title: Target therapy in elderly breast cancer patients.
abstract: Substantial progress has been made in the management of breast cancer by targeting HER2 and VEGF pathways. Although the efficacy and safety of target therapy in breast cancer have been established, no specific phase III trial has addressed these issues in the elderly population and the only data available derive from subanalyses or retrospective series. The aim of this review is to summarize the available evidence in this special population and to encourage further well designed studies in elderly breast cancer patients.
authors.affiliation: Division of Medical Oncology C, National Cancer Institute, Centro di Riferimento Oncologico via Franco Gallini 2, 33081 Aviano, Italy. paolocarli1979@gmail.com
authors.forename: Paolo
authors.initials: P
authors.lastname: Carli
authors.forename: Elisa
authors.initials: E
authors.lastname: Turchet
authors.forename: Daniela
authors.initials: D
authors.lastname: Quitadamo
authors.forename: Antonella
authors.initials: A
authors.lastname: Spada
authors.forename: Gianmaria
authors.initials: G
authors.lastname: Miolo
authors.forename: Elda
authors.initials: E
authors.lastname: Lamaj
authors.forename: Simon
authors.initials: S
authors.lastname: Spazzapan
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Di Lauro
authors.forename: Riccardo
authors.initials: R
authors.lastname: Dolcetti
authors.forename: Andrea
authors.initials: A
authors.lastname: Veronesi
authors.forename: Diana
authors.initials: D
authors.lastname: Crivellari
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D000077341:Lapatinib; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000077341:Lapatinib; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D000068878:Trastuzumab; D042461:Vascular Endothelial Growth Factor A